Thermo Fisher Scientific Inc. (NYSE:TMO) is Contravisory Investment Management Inc.’s 9th Largest Position


Share on StockTwits

Contravisory Investment Management Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,440 shares of the medical research company’s stock after selling 994 shares during the period. Thermo Fisher Scientific comprises about 2.3% of Contravisory Investment Management Inc.’s portfolio, making the stock its 9th largest holding. Contravisory Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $7,503,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of TMO. Larson Financial Group LLC boosted its stake in shares of Thermo Fisher Scientific by 38.5% in the fourth quarter. Larson Financial Group LLC now owns 72 shares of the medical research company’s stock valued at $34,000 after buying an additional 20 shares in the last quarter. Kornitzer Capital Management Inc. KS raised its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 6,921 shares of the medical research company’s stock worth $3,224,000 after purchasing an additional 20 shares during the last quarter. S.A. Mason LLC raised its holdings in Thermo Fisher Scientific by 8.7% during the fourth quarter. S.A. Mason LLC now owns 250 shares of the medical research company’s stock worth $116,000 after purchasing an additional 20 shares during the last quarter. Old Port Advisors raised its holdings in Thermo Fisher Scientific by 1.2% during the fourth quarter. Old Port Advisors now owns 1,849 shares of the medical research company’s stock worth $872,000 after purchasing an additional 22 shares during the last quarter. Finally, CFO4Life Group LLC raised its holdings in Thermo Fisher Scientific by 1.8% during the fourth quarter. CFO4Life Group LLC now owns 1,216 shares of the medical research company’s stock worth $567,000 after purchasing an additional 22 shares during the last quarter. Institutional investors own 87.17% of the company’s stock.

Thermo Fisher Scientific stock opened at $494.38 on Friday. The firm has a market capitalization of $194.30 billion, a P/E ratio of 40.52, a PEG ratio of 1.40 and a beta of 0.85. The stock has a fifty day moving average price of $455.81 and a 200 day moving average price of $472.99. Thermo Fisher Scientific Inc. has a 52 week low of $316.36 and a 52 week high of $532.57. The company has a current ratio of 2.93, a quick ratio of 2.31 and a debt-to-equity ratio of 0.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Sunday, January 31st. The medical research company reported $7.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $6.56 by $0.53. Thermo Fisher Scientific had a return on equity of 21.35% and a net margin of 17.12%. The firm had revenue of $10.55 billion during the quarter, compared to the consensus estimate of $9.53 billion. During the same quarter in the previous year, the business earned $3.55 earnings per share. The firm’s quarterly revenue was up 54.5% compared to the same quarter last year. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, April 16th. Shareholders of record on Tuesday, March 16th will be given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.21%. The ex-dividend date is Monday, March 15th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.22. Thermo Fisher Scientific’s payout ratio is 8.42%.

Several equities analysts recently issued reports on TMO shares. Credit Suisse Group lifted their price objective on Thermo Fisher Scientific from $556.00 to $580.00 in a report on Tuesday, January 12th. Cowen lifted their price objective on Thermo Fisher Scientific from $525.00 to $585.00 and gave the stock an “outperform” rating in a report on Tuesday, February 2nd. UBS Group cut their price target on Thermo Fisher Scientific from $588.00 to $560.00 and set a “buy” rating for the company in a report on Monday, March 29th. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $488.00 price target for the company. in a report on Tuesday, December 22nd. Finally, Stifel Nicolaus boosted their price target on Thermo Fisher Scientific from $530.00 to $600.00 and gave the stock a “buy” rating in a report on Tuesday, February 2nd. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $524.45.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More: Asset Allocation

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.